“Treatment Outcome in Patients With HCV Genotype-3a Infection, Treated With 24-Weeks Dual Therapy (Sofosbuvir and Ribavirin)”. Medical Forum Monthly 28, no. 11 (May 19, 2024). Accessed September 25, 2025. https://medicalforummonthly.com/index.php/mfm/article/view/4275.